DET1 Inhibitors
Chemical inhibitors of DET1 can exert their inhibitory effects through a variety of mechanisms associated with the disruption of protein degradation pathways. Proteasome inhibitors such as MG132, ALLN, Lactacystin, Epoxomicin, Bortezomib, Carfilzomib, and Ixazomib function by blocking the proteolytic activity of the 26S proteasome, an enzyme complex responsible for degrading ubiquitinated proteins. Since DET1 is known to be involved in protein ubiquitination, the inhibition of the proteasome by these chemicals can lead to the accumulation of ubiquitinated proteins. This build-up can include regulatory proteins that are capable of binding to and inhibiting the activity of DET1, thus preventing DET1 from executing its role in the ubiquitin-proteasome pathway. The accumulation of these ubiquitinated proteins within the cell is therefore a key aspect of how these inhibitors can functionally inhibit DET1.
Other inhibitors like Chloroquine and 3-Methyladenine target autophagy, a cellular degradation process that works in parallel with the ubiquitin-proteasome system. By inhibiting autophagy, these chemicals can cause an increase in the cellular protein levels, including those that may interact with and inhibit DET1. Chloroquine raises lysosomal pH, disrupting lysosomal function and autophagic protein degradation, while 3-Methyladenine inhibits class III PI3K, a key enzyme in the initiation of autophagy. Similarly, Concanamycin A and Bafilomycin A1 inhibit the V-ATPase proton pump, consequently preventing vesicle acidification, crucial for lysosomal function. This inhibition can indirectly impact DET1 function by altering the cellular protein degradation environment. Lastly, E-64 as a cysteine protease inhibitor can lead to the disruption of the protein degradation pathway, which can result in the accumulation of cellular proteins that can inhibit DET1.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a potent, reversible, and cell-permeable proteasome inhibitor. DET1 has been shown to be involved in protein ubiquitination. By inhibiting the proteasome, MG132 can prevent the degradation of ubiquitinated proteins, thus potentially leading to the accumulation of proteins that may functionally inhibit DET1. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin is another specific inhibitor of the proteasome. It irreversibly binds to the catalytic site of the proteasome, leading to the accumulation of ubiquitinated proteins, which could indirectly inhibit DET1 by disrupting its mediated processes. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin is a selective and potent inhibitor of the proteasome. By inhibiting proteasomal degradation, it can lead to a buildup of certain regulatory proteins that could bind to and inhibit the functional activity of DET1. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a well-known proteasome inhibitor used for multiple myeloma and mantle cell lymphoma. Through its proteasome inhibition mechanism, it may cause an accumulation of proteins that could suppress the function of DET1. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
Carfilzomib is an irreversible proteasome inhibitor. By blocking proteasomal activity, it could lead to an increase in cellular proteins that may inhibit DET1 activity. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
Ixazomib is a selective proteasome inhibitor. Its mechanism of increasing the levels of ubiquitinated proteins in the cell could indirectly inhibit DET1 by altering the protein degradation pathway in which DET1 is involved. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine is an autophagy inhibitor that raises the lysosomal pH, which can disrupt lysosomal degradation pathways. Although not directly targeting DET1, the inhibition of autophagy can affect cellular protein levels and potentially influence DET1's functional interactions. | ||||||
Autophagy Inhibitor, 3-MA | 5142-23-4 | sc-205596 sc-205596A | 50 mg 500 mg | $65.00 $261.00 | 113 | |
3-Methyladenine is a known inhibitor of autophagy by inhibiting class III PI3K. It could lead to the accumulation of cellular proteins that influence the functional activity of DET1 by perturbing the autophagic degradation of proteins DET1 interacts with. | ||||||
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $66.00 $167.00 $673.00 $2601.00 | 109 | |
Concanamycin A is a specific inhibitor of the V-ATPase proton pump, leading to disrupted acidification of organelles like lysosomes. This disruption can increase the pH levels in lysosomes, potentially affecting the degradation of proteins and indirectly inhibiting DET1 function. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Bafilomycin A1 is another V-ATPase inhibitor that prevents vesicle acidification. By inhibiting lysosomal acidification, it could affect protein turnover and thereby indirectly inhibit DET1 activity. | ||||||